Summary of Study ST000888
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000617. The data can be accessed directly via it's Project DOI: 10.21228/M8X96N This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST000888 |
Study Title | Lyme Disease Biosignature Training (95 MFs) |
Study Type | Metabolomic Analysis |
Study Summary | Retrospective serum samples from patients with early Lyme disease, other diseases, and healthy controls were analyzed for small molecule metabolites by liquid chromatography-mass spectrometry (LC-MS). A metabolomics data workflow was applied to select a biosignature for classifying early Lyme disease and non-Lyme disease patients. A statistical model of the biosignature was trained using the patients' LC-MS data, and subsequently applied as an experimental diagnostic tool with LC-MS data from additional patient sera. |
Institute | Colorado State University |
Department | Department of Microbiology, Immunology, and Pathology |
Laboratory | Belisle |
Last Name | Belisle |
First Name | John |
Address | 200 West Lake, Campus Delivery 0922, Colorado State University, Fort Collins, CO, 80523, USA |
john.belisle@colostate.edu | |
Phone | 970-491-5384 |
Submit Date | 2017-09-05 |
Num Groups | 9 |
Study Comments | All samples and data used in training are provided. All samples and data used in testing are provided, except healthy controls that were experimentally heat treated. |
Publications | https://doi.org/10.1093/cid/civ185 |
Analysis Type Detail | LC-MS |
Release Date | 2017-11-15 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR000617 |
Project DOI: | doi: 10.21228/M8X96N |
Project Title: | Development of a Metabolic Biosignature for Detection of Early Lyme Disease |
Project Type: | MS Study |
Project Summary: | Proof-of-concept studies for a LC-MS metabolite-based biosignature that classifies early Lyme disease patients from non-Lyme disease patients through metabolomics analyses of patient sera. |
Institute: | Colorado State University |
Department: | Department of Microbiology, Immunology, and Pathology |
Laboratory: | Belisle |
Last Name: | Belisle |
First Name: | John |
Address: | 200 West Lake, Campus Delivery 0922, Colorado State University, Fort Collins, CO, 80523, USA |
Email: | john.belisle@colostate.edu |
Phone: | 9704915384 |
Funding Source: | NIAID/NIH/HHS AI100228 |
Publications: | https://doi.org/10.1093/cid/civ185 |
Subject:
Subject ID: | SU000925 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Species Group: | Mammals |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Disease Status |
---|---|---|
SA051651 | EL-NYMC-78-Run 2b | Early Disseminated Lyme |
SA051652 | EL-NYMC-77-Run 2b | Early Disseminated Lyme |
SA051653 | EL-NYMC-76-Run 2b | Early Disseminated Lyme |
SA051654 | EL-NYMC-79-Run 2b | Early Disseminated Lyme |
SA051655 | EL-NYMC-1-Run 2a | Early Disseminated Lyme |
SA051656 | EL-NYMC-83-Run 2b | Early Disseminated Lyme |
SA051657 | EL-NYMC-82-Run 2b | Early Disseminated Lyme |
SA051658 | EL-NYMC-75-Run 2b | Early Disseminated Lyme |
SA051659 | EL-NYMC-80-Run 2b | Early Disseminated Lyme |
SA051660 | EL-NYMC-74-Run 2b | Early Disseminated Lyme |
SA051661 | EL-NYMC-105-Run 4 | Early Disseminated Lyme |
SA051662 | EL-NYMC-104-Run 4 | Early Disseminated Lyme |
SA051663 | EL-NYMC-103-Run 4 | Early Disseminated Lyme |
SA051664 | EL-NYMC-70-Run 2b | Early Disseminated Lyme |
SA051665 | EL-NYMC-71-Run 2b | Early Disseminated Lyme |
SA051666 | EL-NYMC-73-Run 2b | Early Disseminated Lyme |
SA051667 | EL-NYMC-72-Run 2b | Early Disseminated Lyme |
SA051668 | EL-NYMC-84-Run 2b | Early Disseminated Lyme |
SA051669 | EL-NYMC-85-Run 2b | Early Disseminated Lyme |
SA051670 | EL-NYMC-97-Run 2b | Early Disseminated Lyme |
SA051671 | EL-NYMC-96-Run 2b | Early Disseminated Lyme |
SA051672 | EL-NYMC-95-Run 2b | Early Disseminated Lyme |
SA051673 | EL-NYMC-98-Run 2b | Early Disseminated Lyme |
SA051674 | EL-NYMC-99-Run 2b | Early Disseminated Lyme |
SA051675 | EL-NYMC-101-Run 2b | Early Disseminated Lyme |
SA051676 | EL-NYMC-100-Run 2b | Early Disseminated Lyme |
SA051677 | EL-NYMC-94-Run 2b | Early Disseminated Lyme |
SA051678 | EL-NYMC-93-Run 2b | Early Disseminated Lyme |
SA051679 | EL-NYMC-88-Run 2b | Early Disseminated Lyme |
SA051680 | EL-NYMC-87-Run 2b | Early Disseminated Lyme |
SA051681 | EL-NYMC-86-Run 2b | Early Disseminated Lyme |
SA051682 | EL-NYMC-89-Run 2b | Early Disseminated Lyme |
SA051683 | EL-NYMC-90-Run 2b | Early Disseminated Lyme |
SA051684 | EL-NYMC-92-Run 2b | Early Disseminated Lyme |
SA051685 | EL-NYMC-91-Run 2b | Early Disseminated Lyme |
SA051686 | EL-NYMC-102-Run 4 | Early Disseminated Lyme |
SA051687 | EL-NYMC-100-Run 4 | Early Disseminated Lyme |
SA051688 | EL-NYMC-77-Run 4 | Early Disseminated Lyme |
SA051689 | EL-NYMC-76-Run 4 | Early Disseminated Lyme |
SA051690 | EL-NYMC-75-Run 4 | Early Disseminated Lyme |
SA051691 | EL-NYMC-78-Run 4 | Early Disseminated Lyme |
SA051692 | EL-NYMC-79-Run 4 | Early Disseminated Lyme |
SA051693 | EL-NYMC-82-Run 4 | Early Disseminated Lyme |
SA051694 | EL-NYMC-81-Run 4 | Early Disseminated Lyme |
SA051695 | EL-NYMC-80-Run 4 | Early Disseminated Lyme |
SA051696 | EL-NYMC-74-Run 4 | Early Disseminated Lyme |
SA051697 | EL-NYMC-73-Run 4 | Early Disseminated Lyme |
SA051698 | EL-NYMC-33-Run 1a | Early Disseminated Lyme |
SA051699 | EL-NYMC-32-Run 1a | Early Disseminated Lyme |
SA051700 | EL-NYMC-31-Run 1a | Early Disseminated Lyme |
SA051701 | EL-NYMC-34-Run 1a | Early Disseminated Lyme |
SA051702 | EL-NYMC-70-Run 4 | Early Disseminated Lyme |
SA051703 | EL-NYMC-72-Run 4 | Early Disseminated Lyme |
SA051704 | EL-NYMC-71-Run 4 | Early Disseminated Lyme |
SA051705 | EL-NYMC-83-Run 4 | Early Disseminated Lyme |
SA051706 | EL-NYMC-84-Run 4 | Early Disseminated Lyme |
SA051707 | EL-NYMC-96-Run 4 | Early Disseminated Lyme |
SA051708 | EL-NYMC-95-Run 4 | Early Disseminated Lyme |
SA051709 | EL-NYMC-94-Run 4 | Early Disseminated Lyme |
SA051710 | EL-NYMC-97-Run 4 | Early Disseminated Lyme |
SA051711 | EL-NYMC-98-Run 4 | Early Disseminated Lyme |
SA051712 | EL-NYMC-102-Run 2b | Early Disseminated Lyme |
SA051713 | EL-NYMC-99-Run 4 | Early Disseminated Lyme |
SA051714 | EL-NYMC-93-Run 4 | Early Disseminated Lyme |
SA051715 | EL-NYMC-92-Run 4 | Early Disseminated Lyme |
SA051716 | EL-NYMC-87-Run 4 | Early Disseminated Lyme |
SA051717 | EL-NYMC-86-Run 4 | Early Disseminated Lyme |
SA051718 | EL-NYMC-85-Run 4 | Early Disseminated Lyme |
SA051719 | EL-NYMC-88-Run 4 | Early Disseminated Lyme |
SA051720 | EL-NYMC-89-Run 4 | Early Disseminated Lyme |
SA051721 | EL-NYMC-91-Run 4 | Early Disseminated Lyme |
SA051722 | EL-NYMC-90-Run 4 | Early Disseminated Lyme |
SA051723 | EL-NYMC-101-Run 4 | Early Disseminated Lyme |
SA051724 | EL-NYMC-103-Run 2b | Early Disseminated Lyme |
SA051725 | EL-NYMC-81-Run 3 | Early Disseminated Lyme |
SA051726 | EL-NYMC-80-Run 3 | Early Disseminated Lyme |
SA051727 | EL-NYMC-79-Run 3 | Early Disseminated Lyme |
SA051728 | EL-NYMC-82-Run 3 | Early Disseminated Lyme |
SA051729 | EL-NYMC-83-Run 3 | Early Disseminated Lyme |
SA051730 | EL-NYMC-86-Run 3 | Early Disseminated Lyme |
SA051731 | EL-NYMC-85-Run 3 | Early Disseminated Lyme |
SA051732 | EL-NYMC-84-Run 3 | Early Disseminated Lyme |
SA051733 | EL-NYMC-78-Run 3 | Early Disseminated Lyme |
SA051734 | EL-NYMC-77-Run 3 | Early Disseminated Lyme |
SA051735 | EL-NYMC-72-Run 3 | Early Disseminated Lyme |
SA051736 | EL-NYMC-71-Run 3 | Early Disseminated Lyme |
SA051737 | EL-NYMC-70-Run 3 | Early Disseminated Lyme |
SA051738 | EL-NYMC-73-Run 3 | Early Disseminated Lyme |
SA051739 | EL-NYMC-74-Run 3 | Early Disseminated Lyme |
SA051740 | EL-NYMC-76-Run 3 | Early Disseminated Lyme |
SA051741 | EL-NYMC-75-Run 3 | Early Disseminated Lyme |
SA051742 | EL-NYMC-87-Run 3 | Early Disseminated Lyme |
SA051743 | EL-NYMC-88-Run 3 | Early Disseminated Lyme |
SA051744 | EL-NYMC-100-Run 3 | Early Disseminated Lyme |
SA051745 | EL-NYMC-99-Run 3 | Early Disseminated Lyme |
SA051746 | EL-NYMC-98-Run 3 | Early Disseminated Lyme |
SA051747 | EL-NYMC-101-Run 3 | Early Disseminated Lyme |
SA051748 | EL-NYMC-102-Run 3 | Early Disseminated Lyme |
SA051749 | EL-NYMC-104-Run 3 | Early Disseminated Lyme |
SA051750 | EL-NYMC-103-Run 3 | Early Disseminated Lyme |
Collection:
Collection ID: | CO000919 |
Collection Summary: | Sera from early LD patients were collected pretreatment at the initial visit to the clinic. Healthy control serum donors were from endemic and nonendemic regions for LD. |
Sample Type: | Blood |
Treatment:
Treatment ID: | TR000939 |
Treatment Summary: | N/A |
Sample Preparation:
Sampleprep ID: | SP000932 |
Sampleprep Summary: | Small molecule metabolites were extracted from aliquots (20 μL) of sera with 75% (final vol) HPLC grade methanol. An aliquot equivalent to 5 μL of serum was analyzed by LC-MS. |
Sampleprep Protocol Comments: | doi:10.1038/nprot.2011.335 |
Combined analysis:
Analysis ID | AN001450 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | Agilent 1200 |
Column | Poroshell 120,EC-C8(100 x 2.1mm,2.5um) |
MS Type | ESI |
MS instrument type | QTOF |
MS instrument name | Agilent 6520 QTOF |
Ion Mode | POSITIVE |
Units | peak area |
Chromatography:
Chromatography ID: | CH001019 |
Instrument Name: | Agilent 1200 |
Column Name: | Poroshell 120,EC-C8(100 x 2.1mm,2.5um) |
Flow Gradient: | 0-100% non-linear gradient |
Flow Rate: | 0.35 ml/min |
Solvent A: | 100% water; 0.1% formic acid |
Solvent B: | 100% methanol; 0.1% formic acid |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS001340 |
Analysis ID: | AN001450 |
Instrument Name: | Agilent 6520 QTOF |
Instrument Type: | QTOF |
MS Type: | ESI |
Ion Mode: | POSITIVE |
Capillary Voltage: | 2000 V |
Dry Gas Flow: | 8 l/min |
Dry Gas Temp: | 300 |
Fragment Voltage: | 120 V |
Nebulizer: | 45 psi |
Octpole Voltage: | 750 V |
Scanning Cycle: | 666.7 spectra/s |
Scanning Range: | 115 - 1500 Da |
Skimmer Voltage: | 60 V |